Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. TGT

Go back to Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1133.00 -27.95 (2.41%)
Previous Close $1160.95    52 Week High $88.16 
Open $1165.00    52 Week Low $67.88 
Day High $1169.99    P/E 262.27 
Day Low $1132.81    EPS $4.32 
Volume 2,437,568